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Abstract
Purpose: The aim of this study was to compare dosimetric characteristics, monitor unit, and delivery efficiency of 4 different
stereotactic body radiotherapy techniques for the treatment of prostate cancer. Methods: This study included 8 patients with
localized prostate cancer. Dosimetric assets of 4 delivery techniques for stereotactic body radiotherapy were evaluated: robotic
CyberKnife, noncoplanar intensity-modulated radiotherapy, and 2 intensity-modulated arc therapy techniques (RapidArc and
Elekta volumetric-modulated arc therapy). All the plans had equal treatment margins and a prescription dose of 35 Gy in
5 fractions. Results: Statistically significant differences were observed in homogeneity index and mean doses of bladder wall and
penile bulb, all of which were highest with CyberKnife. No significant differences were observed in the mean doses of rectum, with
values of 15.2 + 2.6, 13.3 + 2.6, 13.1 + 2.8, and 13.8 + 1.6 Gy with CyberKnife, RapidArc, volumetric-modulated arc therapy,
and noncoplanar intensity-modulated radiotherapy, respectively. The highest dose conformity was realized with RapidArc. The
dose coverage of the planning target volume was lowest with noncoplanar intensity-modulated radiotherapy. Treatment times
and number of monitor units were largest with CyberKnife (on average 34.0 + 5.0 minutes and 8704 + 1449 monitor units)
and least with intensity-modulated arc therapy techniques (on average 5.1 + 1.1 minutes and 2270 + 497 monitor units).
Conclusion: Compared to CyberKnife, the RapidArc, volumetric-modulated arc therapy, and noncoplanar intensity-modulated
radiotherapy produced treatment plans with similar dosimetric quality, with RapidArc achieving the highest dose conformity.
Overall, the dosimetric differences between the studied techniques were marginal, and thus, the choice of the technique should
rather focus on the delivery accuracies and dose delivery times.
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Introduction
External beam radiotherapy is one of the primary treatment
modalities for patients with a localized prostate cancer (PCa).
Stereotactic body radiation therapy (SBRT) is one of the non-
invasive external beam treatment options. In SBRT, high
degree of anatomic precision and localization are coupled with
very high doses of radiation delivered in a small number of
fractions. Accurate image guidance allows reducing the uncer-
tainty margins and minimizing the radiation-related injury in
adjacent normal tissues.
Clinical studies support the efficacy and safety of SBRT in
PCa with low- to intermediate-risk disease.1-4 Preliminary clin-
ical results support the hypothesis of low a–b ratio (1.4-3 Gy)
in PCa compared to adjacent late-responding tissues, leading to
a significant increase in the therapeutic ratio using hypofrac-
tionation.5,6 Using fewer fractions in SBRT enables efficient
patient throughput and is also more convenient for patients by
reducing the treatment course from 7 to 9 weeks to 1 to 2 weeks.
The aforementioned issues are among the main reasons for the
increased use of SBRT in a localized PCa.
Currently, there are several image-guided techniques
available for exact SBRT dose delivery for the PCa. To date,
most of the clinical studies related to SBRT have been rea-
lized with a CyberKnife (CK) system.2,3 In addition,
intensity-modulated techniques have been used and found
feasible and tolerated for SBRT of PCa.7-9 So far, the results
of comparative studies among CK, RapidArc (RA), and
intensity-modulated radiation therapy (IMRT) have been
rather conflicting because of different patient groups or dis-
similar treatment margins.10-13 On the other hand, the Elekta
volumetric-modulated arc therapy (VMAT) technique has
never been compared against CK or RA radiation dose deliv-
ery techniques with the SBRT of PCa. At present, there is a
limited knowledge of how the dosimetric properties of differ-
ent SBRT treatment modalities compare, although there are
several techniques available.
The aim of this multi-institutional study is to evaluate the
dosimetric differences between the SBRT delivery techniques
of CK, Varian RA, Elekta VMAT, and noncoplanar Brainlab
intensity-modulated radiation therapy (ncpIMRT) for PCa. In
this work, identical computed tomography (CT) data sets and
patient contours were used with every treatment planning sys-
tem (TPS). This ensured a valid dosimetric comparison of dif-
ferent techniques and treatment plans.
Materials and Methods
Patients and Imaging
This retrospective study included 8 patients with PCa consecu-
tively treated with CK system. The summary of the patient
population is given in Table 1. The patients were imaged with
CT (Aquilion LB; Toshiba Medical Systems, Japan) and with
magnetic resonance imaging (Avanto 1.5T; Siemens AG,
Munich, Germany) with a slice thickness of 1 mm. Written
instructions were given to the patients in order to ensure that
they empty their bowel and retain urine in their bladder before
the imaging procedures and the treatments.
Contouring
Target volumes and organs at risk (OARs) were delineated on
the CT images with the aid of the coregistered magnetic reso-
nance images. Prostate was delineated without the seminal vesi-
cles as a clinical target volume (CTV). A planning target volume
(PTV) was created by expanding the CTV by 3 mm posteriorly
and 5 mm in other directions. These margins are clinically used
in Kuopio Cancer Center and are also used in a clinical prostate
SBRT study (ClinicalTrials.gov identifier NCT01764646). The
OARs delineated were bladder, rectum, femoral heads, penile
bulb, and normal tissue (defined as body contour—PTV). Rec-
tum was delineated starting from the anal canal and ending up to
the sigmoid colon. Bladder wall was assumed to be a 4-mm-
thick structure inward from the full bladder.
Treatment Planning Criteria and Constraints
The prescription dose was 35 Gy in 5 fractions. The prescription
dose had to cover at least 95% of the volume of the PTV, with a
requirement of a maximum dose (Dmax) being less than 120% of
the prescribed dose. The dose–volume constraints shown in
Table 2 were categorized as minimum and ambition constraints.
The minimum constraints were compiled from a review article by
Grimm et al.14 The ambition constraints were set as secondary
goals to be met in order to decrease the dose to the normal
tissues, thus lowering the probability of complications.
Treatment Planning and Dose Optimization
To enable a valid comparison between all the systems, the
treatment plans were created with a 6-MV photon energy. Each
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patient was replanned with 4 different techniques, taking into
account the dose constraints in Table 2.
CyberKnife (Accuray Inc, Sunnyvale, California) treatments
were planned with Multiplan (v.4.6.0; Accuray Inc) with a dose
rate of 1000 monitor units (MU)/min using Iris variable aperture
collimator. On average, 8 different aperture sizes were used in
each treatment plan ranging from 12.5 to 60.0 mm. The dose
optimization was performed with a sequential method. The time
reduction tool was used in optimization to enhance the directions
of treatment fields. The final dose calculation was performed
with a high-resolution grid (*2 mm) together with ray tracing
algorithm including the entire 3-dimensional data set. The dose
was normalized to the isodose line of 85% + 2%, which is the
standard approach used in Kuopio University Hospital.
The RA plans were delivered with Novalis Tx (Varian Med-
ical Systems Inc, Palo Alto, California, and Brainlab AG, Feld-
kirchen, Germany) linear accelerator with a Dmax rate of 600
MU/min equipped with a high-definition multileaf collimator
with 2.5-mm leaf width in the center. The treatment plans were
optimized and calculated with Eclipse 10.0.28 (Varian Medical
Systems Inc) TPS using an anisotropic analytical algorithm
(AAA; v.10.0.28). The grid sizes for optimization and dose
calculation were set to 0.3125 and 2 mm, respectively. Each
plan consisted of two 360 coplanar arcs with collimator angle
rotations of 30 and 330. Arc Geometry Tool by Eclipse was
used for creation of the arcs.
Volumetric-modulated arc therapy treatment plans were
created with Monaco (v.3.20.01; Elekta-CMS Inc, St Louis,
Missouri) TPS for Axesse (Elekta Ltd, Crawley, United
Kingdom) linear accelerator with 4.0-mm leaves at isocenter
(Beam Modulator) and a Dmax rate of 600 MU/min. The VMAT
was utilized in a single 360 arc (increments of 30) with
collimator angle rotation of 3. An optimization was performed
in a constrained mode, and the constraints were established
based on biological cost functions. The maximum number of
control points was set to 200, the minimum segment width to
1.0 cm, and the fluence smoothing to medium. The dose cal-
culation was performed with X-ray Voxel Monte Carlo (v.1.6)
algorithm with 1.0% uncertainty per plan and a dose grid of
2.0 mm.
For the prostate SBRT, noncoplanar search spaces have
been reported to improve OAR sparing.15 In this study,
ncpIMRT treatment planning was realized with Eclipse
(v.11.0.31). A 10-field noncoplanar template was applied to all
patients (except 12 fields for #7). The plans were created for
Novalis (Brainlab AG) treatment unit with central leaf width of
3 mm at the isocenter and a Dmax rate of 800 MU/min (limited
to 480 MU/min in this study). The gantry rotation angles (and
corresponding couch rotation angles) were 230 (0), 265 (0),
330 (0), 30 (0), 95 (0), 130 (0), 50 (330), 310 (30),
290 (10), and 70 (350). The optimization objectives were
defined with physical dose points for the PTV, rectum, and
bladder wall. The smoothing factor was set to 30, and the
number of iterations to 70. Both the optimization and dose
calculation were performed by AAA (v.11.0.31), with a reso-
lution of 2.5 mm.














1 T1c 3 þ 4 74 122 94 234 0.9 9.1
2 T2a 3 þ 4 29 61 35 330 1.2 5.3
3 T1c 3 þ 3 59 106 41 155 0.4 7.3
4 T1c 3 þ 3 36 71 73 98 0.9 3.1
5 T3 4 þ 4 66 113 69 164 1.4 8.4
6 T1c 4 þ 4 39 76 40 166 0.3 4.2
7 T1c 3 þ 3 44 85 97 245 2.2 10.2
8 T2 2 þ 2 39 74 41 91 0.4 3.9
Mean 48 + 16 88 + 22 61 + 25 185 + 80 1.0 + 0.6 6.4 + 2.7
Abbreviation: PTV, planning target volume.
Table 2. Dose Constraints for Treatment Planning.
Rectum Bladder Wall Penile Bulb Femoral Heads Normal Tissue
Minimum constraints Dmax < 38 Gy Dmax < 38 Gy D3cm
3 < 30 Gy D10cm3 < 30 Gy CI  1.25
D1cm3 <36 Gy D5cm3 <37.5 Gy
D20cm3 <25 Gy D15cm3 <18.3 Gy
V18Gy < 50%
Ambition constraints D4cm3 < 32 Gy D2cm3 < 36.25 Gy D10cm3 < 18 Gy D4cm3 < 18 Gy CI  1.15
D20cm3 < 16 Gy D4cm3 < 32.62 Gy
D10cm3 < 18.12 Gy
Abbreviations: CI, conformity index; Dmax, maximum dose.
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Plan Comparison Parameters
The number of MUs and the treatment delivery efficiency were
evaluated from the treatment plans. Imaging time was not con-
sidered in the radiation delivery efficiency. The dosimetric prop-
erties were evaluated using dose–volume histograms (DVHs)
and were assessed by dose constraints given in Table 2 and by
dose coverage (dose to 99% of the PTV volume, D99), homo-
geneity, and conformity of the PTV. A homogeneity index (HI)
was defined as a difference between D1 and D99 divided by the
prescription dose. A conformity index (CI) was expressed as a
ratio of volume covered by both the prescription isodose and the
PTV volume. The calculations of statistical significance were
performed with SPSS (v.19.0.0; IBM, New York) using linear
mixed models for testing the patient variance and 1-way analysis
of variance to determine the significant differences.
Results
Typical dose distributions of each technique are shown in Fig-
ure 1. The cumulative DVHs for the PTV, rectum, and bladder
wall of the 8 patients are shown in Figure 2. The average pre-
scription dose coverage of the PTVs was 96.0% + 1.7%, 96.0%
+ 0.0%, 95.3% + 0.2%, and 95.0% + 0.3% with CK, RA,
VMAT, and ncpIMRT, respectively. The corresponding cov-
erage of the CTVs was 99.5% + 0.0%, 99.8% + 0.2%, 99.4%
+ 0.4%, and 99.9% + 0.5%. An average number of MUs and
the mean beam-on times with 1 fraction were greatest with CK
(data given in Table 3). The mean values for D1cm3, D99, HI,
and CI are summarized in Table 3 and other dosimetric quan-
tities in Table 4. Significant pairwise differences were evalu-
ated with the linear mixed models. The mean doses to the
prostate and the PTV were significantly higher (P < .001) in
CK plans compared to the plans of other techniques. The mean
dose to the bladder wall was on average 3.4 Gy (P < .05) higher
in the CK plans. Also, the mean dose to the penile bulb (P <
.05) and the Dmax to rectum (P < .05) were the highest with CK
plans.
The minimum dose constraints were exceeded with
4 patients in CK (total of 8 violations) and VMAT (5 viola-
tions) and with 3 patients in RA (5 violations) and ncpIMRT
Figure 1. Typical dose distributions for 1 patient (#4) planned with CK (A), RA (B), VMAT (C), and ncpIMRT (D). CK indicates CyberKnife;
ncpIMRT, non-coplanar intensity-modulated radiation therapy; RA, RapidArc; VMAT, volumetric-modulated arc therapy.
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(5 violations). The minimum dose constraints that were met
with every patient and treatment plan were D50% <18 Gy for
rectum, D5cm3 <37.5 Gy for bladder wall, and constraints for
penile bulb, femoral heads, and the CI.
Discussion
Previously, extensive dosimetric comparisons between the
CK and intensity-modulated techniques in PCa have not been
performed. The existing literature comparing different tech-
niques is very limited and to some extent conflicting.10-13
Hossain et al11 observed no significant differences in rectal
and bladder doses between the plans of CK and coplanar
IMRT, although CK had a significant advantage over IMRT
in V30% and V40% of the rectum. King et al12 detected
significant sparing of bladder and rectum with CK compared
to IMRT treatment plan. In contrast, MacDougall et al13
found no dosimetric advantage of choosing CK over RA,
although RA had a small advantage over CK in the lower dose
areas of bladder and rectum. In the latter study, the treatment
margins were not equal between the 2 techniques compared.
All existing studies performed with CK system have also been
executed with 2 fixed collimators rather than Iris collimator,
which allows more time-efficient use of various apertures and
could increase the treatment plan quality, since the plans will
be accomplished with optimum aperture sizes.
In this study, the dosimetric properties between the CK,
ncpIMRT, RA, and VMAT techniques were investigated. The
mean dose to the prostate (P < .001), PTV (P < .001), bladder
wall (P < .05), and penile bulb (P < .05) were significantly
higher with CK as was the Dmax of the bladder wall (P < .05).
The mean bladder wall dose being highest with CK is explained
by the noncoplanar nature of the delivery system and due to the
system’s mechanical inability to irradiate directly from both
lateral directions. The consequence of this can be seen in the
DVH of the bladder wall in Figure 2, as the low dose area is
larger in volume with CK in comparison to the plans of the
other techniques. This effect can also be observed in the mean
dose of the penile, which was highest with CK dose delivery. In
this study, both the minimum and the ambition dose constraints
set for penile bulb were met for every patient with every tech-
nique. It should however be noted that the mean dose received
by the penile bulb has been found to correlate with erectile
dysfunction, and thus, it is suggested to limit the dose below
50 Gy for 90% of the bulb with conventional fractionation.16
The minimum planning requirements were not fulfilled with
every treatment plan. With 4 patients (#1, #3, #5, and #7), the
base of the prostate was inside the apical bladder (average
overlap of 8.8 cm3) making it difficult to achieve the treatment
goals. The average values for V18 of the bladder wall in this
study (23.7% + 4.6%, 20.9% + 5.4%, 26.0% + 6.8%, and
20.4% + 5.5% for CK, RA, VMAT, and ncpIMRT, respec-
tively) were on average larger than the reported values of
Figure 2. Averaged cumulative DVHs of PTV (A), rectum (B), and
bladder wall (C) for CK, RA, VMAT, and ncpIMRT treatment plans
(n ¼ 8 patients). CK indicates CyberKnife; DVH, dose–volume his-
togram; ncpIMRT, non-coplanar intensity-modulated radiation ther-
apy; PTV, planning target volume; RA, RapidArc; VMAT, volumetric
modulated arc therapy.
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MacDougall et al13 (13.2% and 10.4% for CK and RA, respec-
tively) or Hossain et al11 (18% and 21% for CK and IMRT,
respectively), which underlines the challenging anatomy of our
patient group. In this work, the percentage of the rectum receiv-
ing more than 18 Gy (V18) was 31.6% + 10.0%, 27.2% +
10.2%, 27.0% + 9.2%, and 28.1% + 4.2% on average for CK,
RA, VMAT, and ncpIMRT, respectively. The corresponding
values of MacDougall et al13 were 31.9% and 24.8% for CK
and RA and 13% and 19% for CK and IMRT, respectively,
approximated from DVH data of Hossain et al.11 It should also
be underlined that in our study, the treatment margins were
kept equal with every technique investigated unlike in the study
of MacDougall et al.
The patient-specific and unpredictable prostate motion dur-
ing SBRT dose delivery should be considered since there are
only a few fractions with which the dose is delivered, and the
treatment duration is usually greater than 4 to 6 minutes.17 The
CK unit is equipped with 2 orthogonal X-ray imaging devices
for automated image guidance. The system utilizes gold fidu-
cials to track and account for the prostate motion throughout
the treatment delivery. With the CK dose delivery, there is no
need to stop the treatment to correct for the intrafraction posi-
tion changes, since the robotic system will take the movements
into account during the dose delivery based on the intrafrac-
tional orthogonal X-ray images of the gold fiducials. There are
also techniques available for real-time prostate tracking to
Table 4. Average Dosimetric Parameters for 4 Techniques Studied.a
Structure CK, Mean + SD RA, Mean + SD VMAT, Mean + SD ncpIMRT, Mean + SD
Mean values
Prostate, Gy 38.3 + 0.6b 36.4 + 0.4 36.8 + 0.5 36.9 + 0.5
PTV, Gy 37.8 + 0.4b 36.2 + 0.4 36.5 + 0.3 36.6 + 0.4
Rectum, Gy 15.2 + 2.6 13.3 + 2.6 13.1 + 2.8 13.8 + 1.6
Bladder wall, Gy 13.8 + 2.5b 9.9 + 2.3 11.3 + 2.2 9.9 + 2.2
Left femur, Gy 5.4 + 2.1 5.1 + 2.3 8.5 + 2.6 7.1 + 2.5
Right femur, Gy 4.7 + 1.4 5.2 + 2.2 7.9 + 2.5 6.4 + 2.3
Penile bulb, Gy 17.6 + 7.1b 5.9 + 4.4 7.8 + 5.8 9.8 + 7.0
Minimum constraints
Rectum
Dmax < 38 Gy 38.0 + 0.9
b 37.1 + 0.5 37.1 + 0.5 37.1 + 0.4
D1cm3 < 36 Gy 35.1 + 1.1 35.0 + 0.7 34.5 + 1.0 35.1 + 0.8
D20cm3 < 25 Gy 16.1 + 5.0 14.1 + 4.6 14.1 + 7.2 15.0 + 4.1
D50% < 18 Gy 12.5 + 2.9 11.0 + 2.9 10.0 + 3.5 11.6 + 2.2
Bladder wall
Dmax < 38 Gy 37.9 + 0.8 37.8 + 0.4 37.1 + 0.4 37.6 + 0.6
D5cm3 < 37.5 Gy 33.9 + 2.4 32.3 + 3.6 33.9 + 1.7 31.4 + 5.8
D15cm3 < 18.3 Gy 17.2 + 2.0 14.3 + 6.1 18.7 + 8.7 14.8 + 6.0
Ambition constraints
Rectum
D4cm3 < 32 Gy 31.1 + 2.5 29.8 + 2.5 29.7 + 3.3 30.5 + 2.2
D20cm3 < 16 Gy 16.1 + 5.0 14.1 + 4.6 14.1 + 7.2 15.0 + 4.1
Bladder wall
D2cm3 < 36.25 Gy 36.3 + 0.8 36.0 + 0.4 35.7 + 0.4 35.8 + 1.3
D4cm3 < 32.62 Gy 34.9 + 1.7 34.0 + 2.1 34.7 + 1.1 33.1 + 4.3
D10cm3 < 18.12 Gy 25.7 + 5.2 23.5 + 7.4 26.5 + 7.9 22.4 + 7.4
Abbreviations: CK, CyberKnife; ncpIMRT, noncoplanar intensity-modulated radiation therapy; RA, RapidArc; SD, standard deviation; VMAT, volumetric-
modulated arc therapy.
aN ¼ 8 Patients.
bThe mean value differs significantly (P < .05) from the value of the other techniques.




Beams/Arcs Number of MUs/fr
Treatment Time,
minutes D1cm3, Gy D99, Gy CI HI
CyberKnife 195 + 34 8704 + 1449a 34.0 + 5.0a 40.3 + 0.7a 33.5 + 0.9 1.11 + 0.02 0.19 + 0.02a
RapidArc 2 + 0 2623 + 521 4.6 + 0.9 37.3 + 0.8 33.8 + 0.7 1.02 + 0.04a 0.10 + 0.04
Elekta VMAT 1 + 0 2192 + 498 5.5 + 1.8 37.9 + 0.7 33.8 + 0.5 1.10 + 0.02 0.12 + 0.03
ncpIMRT 10.3 + 0.7 2953 + 473 6.2 + 1.0 37.6 + 0.4 32.7 + 0.7a 1.12 + 0.05 0.14 + 0.03
Abbreviations: CI, conformity index; D99, dose to 99% of the structure volume; HI, homogeneity index; MU, monitor unit; ncpIMRT, noncoplanar intensity-
modulated radiation therapy; VMAT, volumetric-modulated arc therapy.
aThe mean value differs significantly (P < .05) from the value of the other techniques.
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achieve submillimeter accuracy with the intensity-modulated
arc therapy techniques.18,19 As the intrafractional movement of
the prostate correlates strongly with time, the RA and VMAT
techniques benefit of having the shortest beam-on times (on
average 5.1 minutes) when compared to ncpIMRT (8.3 min-
utes) and CK (34 minutes). The use of a higher dose rate,
available in a flattening filter-free (FFF) dose delivery, would
further reduce the treatment time. With the FFF techniques, the
mean dose delivery duration can be reduced down to 2 to
3 minutes when using a dose rate of 2400 MU/min.9 Thus, the
linac-based systems do benefit from being more time efficient.
This study is limited by a relatively small size of the patient
group, although the observations were very consistent with
every patient, and no statistical random effects were recorded
within the patient data. It should also be noted that more clin-
ical data are needed on the safety and efficacy of SBRT among
clinical patient cohorts, especially in high-risk patients with
PCa, which were also included in our dosimetric study.
Another limitation of the study is the fact that the SBRT plan-
ning requires advanced skills, and the dosimetric results can be
somewhat planner dependent, although all the treatment plans
were generated by experienced planners. Likewise, the optimi-
zation criteria used with different planning systems can vary
greatly. Subsequently, some compromises regarding the typical
treatment planning for the different equipment were made in
this study to standardize the treatment plans and make them
better comparable. Therefore, for example, noncoplanar arc
fields or more than 1 photon energy were not allowed in this
study, although they might have been used in clinical practice.
We also acknowledge that the study did not consider inter- or
intrafractional positioning or delivery accuracy of the studied
techniques. Nonetheless, like stated earlier, there are tech-
niques available for every dose delivery system to take into
account these inaccuracies. It should also be considered that
the treatment margins used in this study could need the use of a
6-dimensional robotic couch to correct the rotational deviations
of the prostate. Radiobiological aspects of the extended treat-
ment delivery times, dose heterogeneity inside PTV, or hetero-
geneity of the PCa were not considered in this study.5,20,21 It
should, however, be underlined that the high-dose areas inside
the prostate and PTV were significantly (P < .001) higher with
CK than with the other techniques studied. These higher doses
inside the prostate gland could have a positive effect on the
tumor control probability. However, the effect of the dose het-
erogeneity to the biochemical control was not in the scope of
this investigation, but it needs further clinical studies to eval-
uate its possible effects.
Conclusion
In this study, the dosimetric differences between the explored
techniques were small. The major differences between the
techniques were mainly related to dose delivery characteristics
of the CK system, resulting in higher maximum doses in the
target and larger low dose volumes in the studied OARs. The
dosimetric properties between the studied techniques were
relatively similar, and thus, the comparison of the delivery
systems in clinical practice should focus on factors such as
dose delivery accuracies, beam-on and delivery times, and the
compensation of inter- and intrafractional positional errors.
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21. Seppälä J, Seppänen M, Arponen E, Lindholm P, Minn H.
Carbon-11 acetate PET/CT based dose escalated IMRT in pros-
tate cancer. Radiother Oncol. 2009;93(2), 234-240. doi:10.1016/
j.radonc.2009.08.010.
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